New Probi bacteria in a European food deal Probi has signed a license agreement with a well-established European food company. The agreement gives the company exclusive rights to sell products containing one of Probi´s bacteria that has not yet been commercialized. The company wishes to remain anonymous until the product is launched, which is expected at the end of 2007. “We are proud to announce this food deal and we see great potential in this new cooperation. With this license, Probi is commercializing a new probiotic bacteria on the international food market,” says Niklas Bjärum, Probi's Director of Marketing and Sales for Functional Food. “This license agreement confirms yet again the substantial international interest in Probi´s probiotics. The increasing interest in our new concepts and our list of renowned license partners reflect the market demand for quality products with health benefits.” Probi's new partner, a major vendor of chilled beverages, is well positioned to commercialize the product and achieve strong sales results on the European market. “We are currently collaborating on the commercialization and we expect a launch at the end of the year. We have agreed a fixed royalty of 300.000 € for 2008, followed by royalties on sales of products containing our bacteria. The royalty is expected to increase as products are launched in new European markets”, added Per-Ola Forsberg, Probi's Executive Vice President. Probi's business area Functional Food supports its clients in the commercialization process of probiotic products with health benefits. The estimated total value of the global market for probiotic functional food is some 90 billion SEK, with an annual growth rate of over 19% in recent years. For further information, contact: Per-Ola Forsberg, executive Vice President, tel: +46 (0)46 286 8926 or +46 (0)73 344 8384 e-mail: per-ola.forsberg@probi.se Niklas Bjärum, Marketing & Sales Director Functional Food, tel. +46 (0)46 286 8967 or +46 (0)70 538 8864, e-mail: niklas.bjarum@probi.se Rolf Bjerndell, Acting CEO, tel: +46 (0)46 286 8923 or +46 (0)70 515 3009 e-mail: rolf.bjerndell@probi.se About Probi Probi is a leading player in probiotic research and development. The company's research is carried out using living micro- organisms with scientifically proven health effects. The main research areas are: stomach and gastrointestinal tracts, immune defense, risk factors for cardiovascular diseases, stress and recovery. Probi's business concept is based on offering efficient and well-documented probiotic product concepts with comprehensive patent protection, which result in the possibility of considerably higher royalty levels than for the sector as a whole. Probi's customers include leading companies in the functional foods, dietary supplements and clinical nutrition marketing areas. Since the middle of the 1990s, the Company has had continuous income from commercialized products. The global market for probiotic products shows a favorable underlying growth. New insight into the advantages of probiotics, an increasingly greater health interest and authorities' increasing documentation demands and regulations are the primary trends that support Probi. Probi's shares are listed on the Nordic Exchange. For further information, visit www.probi.se.
New Probi bacteria in a European food deal
| Source: Probi AB